Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.21 USD | +0.53% | +4.90% | -6.49% |
09-13 | RBC Raises Price Target on Illumina to $252 From $242, Keeps Outperform Rating | MT |
09-06 | European Commission Withdraws Previous Decisions on Illumina-Grail Merger After Court Ruling | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 3.54B | 3.24B | 4.53B | 4.58B | 4.5B | |||||
Total Revenues | 3.54B | 3.24B | 4.53B | 4.58B | 4.5B | |||||
Cost of Goods Sold, Total | 1.04B | 1.01B | 1.3B | 1.44B | 1.56B | |||||
Gross Profit | 2.5B | 2.23B | 3.22B | 3.14B | 2.94B | |||||
Selling General & Admin Expenses, Total | 864M | 949M | 1.57B | 1.57B | 1.64B | |||||
R&D Expenses | 575M | 609M | 935M | 1.22B | 1.21B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 34M | 28M | 71M | 173M | 191M | |||||
Other Operating Expenses, Total | 1.47B | 1.59B | 2.57B | 2.97B | 3.04B | |||||
Operating Income | 1.03B | 645M | 652M | 179M | -94M | |||||
Interest Expense, Total | -52M | -49M | -61M | -26M | -77M | |||||
Interest And Investment Income | 75M | 41M | - | 11M | 58M | |||||
Net Interest Expenses | 23M | -8M | -61M | -15M | -19M | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | 4M | 32M | 9M | -13M | 1M | |||||
EBT, Excl. Unusual Items | 1.06B | 669M | 600M | 151M | -112M | |||||
Restructuring Charges | - | - | - | -30M | -152M | |||||
Merger & Related Restructuring Charges | -43M | -117M | -745M | - | - | |||||
Impairment of Goodwill | - | - | - | -3.91B | -712M | |||||
Gain (Loss) On Sale Of Investments | 53M | 270M | 917M | -122M | -40M | |||||
Gain (Loss) On Sale Of Assets | 54M | - | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
In Process R&D Expenses | - | - | - | - | -115M | |||||
Legal Settlements | - | 27M | - | -619M | -20M | |||||
Other Unusual Items | -1M | 7M | 112M | 198M | 34M | |||||
EBT, Incl. Unusual Items | 1.12B | 856M | 884M | -4.34B | -1.12B | |||||
Income Tax Expense | 128M | 200M | 122M | 68M | 44M | |||||
Earnings From Continuing Operations | 990M | 656M | 762M | -4.4B | -1.16B | |||||
Net Income to Company | 990M | 656M | 762M | -4.4B | -1.16B | |||||
Minority Interest | 12M | - | - | - | - | |||||
Net Income - (IS) | 1B | 656M | 762M | -4.4B | -1.16B | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 1B | 656M | 762M | -4.4B | -1.16B | |||||
Net Income to Common Excl. Extra Items | 1B | 656M | 762M | -4.4B | -1.16B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6.82 | 4.46 | 5.08 | -28.05 | -7.35 | |||||
Basic EPS - Continuing Operations | 6.82 | 4.46 | 5.08 | -28.05 | -7.35 | |||||
Basic Weighted Average Shares Outstanding | 147M | 147M | 150M | 157M | 158M | |||||
Net EPS - Diluted | 6.74 | 4.45 | 5.04 | -28.05 | -7.35 | |||||
Diluted EPS - Continuing Operations | 6.74 | 4.45 | 5.04 | -28.05 | -7.35 | |||||
Diluted Weighted Average Shares Outstanding | 149M | 148M | 151M | 157M | 158M | |||||
Normalized Basic EPS | 4.57 | 2.84 | 2.5 | 0.6 | -0.44 | |||||
Normalized Diluted EPS | 4.51 | 2.83 | 2.48 | 0.6 | -0.44 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.22B | 832M | 903M | 573M | 338M | |||||
EBITA | 1.06B | 676M | 727M | 358M | 103M | |||||
EBIT | 1.03B | 645M | 652M | 179M | -94M | |||||
EBITDAR | 1.29B | 905M | 986M | 665M | 461M | |||||
Total Revenues (As Reported) | 3.54B | 3.24B | 4.53B | 4.58B | 4.5B | |||||
Effective Tax Rate - (Ratio) | 11.45 | 23.36 | 13.8 | -1.57 | -3.94 | |||||
Current Domestic Taxes | 39M | 38M | 91M | 16M | 1M | |||||
Current Foreign Taxes | 84M | 45M | 107M | 75M | 77M | |||||
Total Current Taxes | 123M | 83M | 198M | 91M | 78M | |||||
Deferred Domestic Taxes | 0 | 124M | -73M | -7M | -39M | |||||
Deferred Foreign Taxes | 5M | -7M | -3M | -16M | 5M | |||||
Total Deferred Taxes | 5M | 117M | -76M | -23M | -34M | |||||
Normalized Net Income | 671M | 418M | 375M | 94.38M | -70M | |||||
Interest on Long-Term Debt | 52M | 49M | 61M | 26M | 77M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 28M | 28M | 48M | 53M | 36M | |||||
Research And Development Expense From Footnotes | 647M | 682M | 1.18B | 1.32B | 1.35B | |||||
Net Rental Expense, Total | 72M | 73M | 83M | 92M | 123M | |||||
Imputed Operating Lease Interest Expense | 15.45M | 15.11M | 18.22M | 6.28M | 26.05M | |||||
Imputed Operating Lease Depreciation | 56.55M | 57.89M | 64.78M | 85.72M | 96.95M | |||||
Stock-Based Comp., COGS (Total) | 23M | 25M | 27M | 32M | 36M | |||||
Stock-Based Comp., R&D Exp. (Total) | 66M | 74M | 276M | 153M | 155M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 105M | 95M | 638M | 181M | 189M | |||||
Total Stock-Based Compensation | 194M | 194M | 941M | 366M | 380M |